Microdosing Programmes
Fractional dosing, priced separately for a reason.
Fractional dosing, priced separately for a reason.
Across the 20 programmes we price, all-in cost runs from $145 a month at the starter dose, with the cheapest first year at about $1,740 (NexLife, $145 a month at a 2.4 mg maintenance dose). Every figure on this page is on that same all-in basis.
All-in monthly cost = medication + any recurring fee, at a named dose, before tax and before prepaid discounts. Captured 2026-08-05. How we verify a price.
What escalating the dose does to your bill
Where this sits in the decision
Brand and compounded are different products under different regulatory regimes at very different prices. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing. Brand product is reviewed, metered and traceable, and costs more. Both are legitimate choices; only one of them is often described as the other.
What the price difference actually buys
Pre-market review of that specific product, standardised metered dosing in a device, a manufacturer quality system and full supply-chain traceability. Whether that is worth the annual difference is a personal judgement, and anyone telling you the two are simply equivalent is glossing a real distinction.
Coverage changes the answer
Insurance covers indications rather than molecules, and compounded preparations are effectively a cash market. A covered brand prescription at a modest copay beats every compounded route; an uncovered brand prescription rarely does. Establish which you face before comparing prices.
Why this distinction changes what you pay
Every structural difference in this market resolves into money at a maintenance dose. Whether a programme charges a membership, whether it reprices with the dose, whether it demands a term, and whether it bundles or splits its charges together account for most of the gap between the cheapest tracked first year at $1,740 and the most expensive.
None of those differences is visible in an advertised headline figure, which is the reason this site exists in the form it does.
How to act on it this week
Price the dose you expect to maintain on rather than the starter dose. Add every recurring fee. Ask whether the quoted rate holds at renewal. Establish who compounds the medicine. And do not enter a prepaid term until you have held a maintenance dose for a cycle.
Those five steps take under an hour and reliably beat any amount of comparison reading, because they surface the information that comparison tables omit.
How this connects to what you will actually pay
Everything in this section resolves to one number: the all-in monthly cost at the dose you end up holding. Across the 20 programmes we price, that runs from $145 at the cheapest tracked route to several times that at the most expensive, for the identical molecule from the same category of licensed pharmacy.
4 of those programmes charge a recurring platform fee on top of medication and 19 hold one price at every strength. Those two facts explain most of the spread between advertised prices and real ones.
What we could verify and what we could not
4 of 32 tracked programmes have a price we read at the provider or manufacturer. The rest carry third-party figures we have not confirmed, or publish nothing we can interpret. Every table on this site marks which is which, and the comparison matrix lets you filter to verified prices only.
Where we have checked a third-party figure against a provider's own page, it has almost always moved — and it has moved upward. Promotional first months, prepaid bundle rates and medication-only figures that exclude memberships are all published as ongoing all-in prices. Assume an unverified figure is optimistic.
The regulatory distinction that sits under all of this
Compounded semaglutide is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. The active molecule is the same as the branded product; the pre-market review is not, and the assurance comes instead from the pharmacy, the state board that licenses it and, at good operations, batch sterility and potency testing.
That is a legitimate framework rather than a loophole, and it is also why the price is lower. It puts more of the verification burden on the patient, which is the honest trade being made.
Two products, two regimes, two prices
Brand semaglutide is FDA-approved, metered, traceable and priced accordingly. Compounded semaglutide is not FDA-approved and is not reviewed for safety, effectiveness or quality before marketing; it costs a fraction as much, currently from $145 at the starter dose.
Both are legitimate choices. Only one of them is routinely described as the other, and that description is what regulators have acted on.
Coverage decides more of this than price does
Insurance covers indications rather than molecules, and compounded preparations are effectively a cash market. A covered brand prescription at a modest copay beats every cash route here; an uncovered one rarely does.
Establish which you face before comparing prices, because the answer changes the entire calculation rather than shifting it slightly.
What changed during 2026
Manufacturer self-pay pricing fell, a metered pen reached self-pay and retail pickup, and a flat public co-pay arrived for eligible Medicare beneficiaries. The gap the compounded market relied on narrowed from the top.
Comparisons anchored on list price — which is most of them — now overstate the compounded advantage by a wide margin.
Reading this against the rest of the decision
This sits inside a decision with three parts: what you pay at the dose you hold, who makes what you are injecting, and what happens if you stop. Most published guidance covers the first and treats the other two as footnotes.
They are not footnotes. A price advantage of a few hundred dollars a year is erased by one interrupted month, and an interruption is a clinical event rather than an inconvenience — semaglutide takes sixteen weeks to re-titrate from the starter dose.
Which is why this section exists separately from the pricing pages, and why the verification steps on it are worth completing even when the programme you are considering is the cheapest on the site.
What to do with this before you enrol
Turn it into two or three questions you can send in an email. Anything here that cannot be converted into a question a programme could answer in writing is context rather than a check, and context does not protect you.
The programmes that answer promptly and specifically are, in our reading of the public record, rarely the ones patients later write about. That is a weak signal rather than evidence, but it costs nothing to collect and it arrives before your money does.
If a programme declines to answer, that is an answer. The market currently offers 20 priced alternatives, the cheapest verified at $145 a month all-in at a maintenance dose.
What the spread actually represents
All-in cost runs $145 to $324 a month for the same molecule from the same category of licensed pharmacy. That gap is not the medicine. It is overhead, clinical wrap, sourcing and margin, plus how aggressively a programme is willing to structure its fees.
4 of 20 charge a mandatory recurring fee and 19 hold one price at every strength. Those two facts explain most of the spread, and neither appears in a headline figure.
Where our numbers could be wrong
A programme changed its price after our capture date. A third-party figure we recorded does not survive checking. A promotional rate was published as a standing one. Or a programme publishes something we could not find.
All four are live risks and the first is near-certain over time. Every figure carries its capture date and a link to the source we read, so the check takes about two minutes and does not require trusting us.
Why the cheapest entries are the least reliable
Four distortions push in the same direction: a promotional first month quoted as a standing rate, a prepaid bundle rate quoted as monthly, a medication figure that excludes a mandatory membership, and occasionally a different molecule's price in the wrong column.
Every one of those makes a programme look cheaper than it is, which is why the bottom of any published table is where errors concentrate. It is also why we mark which figures we read at the provider and which we did not, rather than presenting one confident list.
Where we have been able to check an unconfirmed figure against a provider's own page, the number usually moved upward.
How to sanity-check any figure you find elsewhere
Three questions. What dose does it describe? Does it include every recurring fee? And when was it captured? A price failing any of the three is not comparable to the numbers here, and most published figures fail at least one.
Semaglutide makes this worse than most categories because the same molecule sells under several brands at prices spanning more than fifteenfold. 'Semaglutide costs X' is not a sentence that can be true without naming the product and the channel.
The short version of microdosing programmes
Price the dose you expect to hold, not the one in the advertisement. Add every recurring fee. Verify the pharmacy. Everything else on this page is detail underneath those three.
Done properly the answer is usually one of a handful of programmes: the cheapest verified route runs $145 a month all-in, about $1,740 across a first year including titration.
The next step that actually moves things
Send two or three programmes the same five questions: total at 2.4 mg including every fee, which pharmacy, is the prescriber licensed in my state, what notice to cancel and what is refundable, and which form of the active ingredient is used.
Whoever answers all five in writing has told you more than any comparison table can, this one included. Whoever does not has also told you something.
One thing worth doing annually
Re-price the market at your actual maintenance dose. No programme notifies existing patients when a competitor drops below it, and semaglutide pricing moved repeatedly through 2025 and 2026 — manufacturer cuts, an oral option, a higher-dose product, and several platforms leaving compounded entirely.
An hour once a year is a poor use of time for most purchases and an excellent one for a medication you may take for years.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.